Share on StockTwits
 

LIGHTNING RELEASES (02/14/2014) - Oval Medical Technologies Limited (“Oval”), a leading auto-injector company, has named Dr. Paul Harper as Chairman of the Board. He will be succeeding Peter Keen after his three-year tenure.  Peter has now taken the position of Chief Executive at investment fund Cambridge Innovation Capital.

Dr Harper took up the role at Oval in January 2014, and joins with over 30 years of experience in drug development and medical devices. He has an extensive background as an Executive Director, NED and Company Chairman of developing Pharma and biotech companies. Dr Harper has served as Chairman for several AIM listed companies in the drug discovery space. Paul found Provensis Ltd, a BTG subsidiary, to develop a pioneering drug/device combination product and served as Chairman at Monica Healthcare Ltd., a company developing a wireless foetal heart monitor that has secured US deals worth $10m. He was formally Director of Research & Development at Johnson & Johnson Ltd, and CEO of Cambridge Antibody Technology Ltd.  He is the author of over 50 publications and patents.

Announcing the appointment, Oval’s CEO Barbara Lead said, “On behalf of the Board I would like to welcome Paul and I look forward to working closely with him as we continue to focus on Oval’s innovation and growth. Paul brings a wealth of expertise and his input will be invaluable in aiding the commercialisation of Oval’s auto-injector technology. I would like to express my gratitude to Peter Keen for his leadership and the pivotal role he has played in the success of the company to this point.”

Dr Harper said that he was “…delighted to be joining a Company with such innovative technology and with a team of talented and experienced individuals with most of the skills required to work with major pharma clients to introduce products into the marketplace.  I believe that the Company is poised to move to the next level and it will give me immense pleasure to facilitate this process.”

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.